Nivolumab單抗注射劑市場規模、佔有率和成長分析：按適應症、療法、最終用戶、分銷管道、劑量強度和地區分類－2026-2033年產業預測

2024 年全球Nivolumab單抗注射劑市場價值為 8.745 億美元，預計到 2025 年將從 9.2522 億美元成長到 2033 年的 14.5255 億美元，在預測期（2026-2033 年）內以 5.8% 的複合年成長率成長。

全球Nivolumab單抗注射劑市場是一個關鍵細分市場，其核心是一種PD-1抑制劑單株抗體，能夠幫助免疫系統有效靶向惡性細胞。該藥物是治療惡性黑色素瘤、非小細胞肺癌和腎細胞癌等疾病的重要手段，為百時美施貴寶等製藥公司創造了可觀的收入。健保報銷範圍的擴大是推動市場成長要素，因為保險公司越來越認知到該藥物對患者整體存活率的影響，尤其是在轉移性黑色素瘤患者中，這導致其在處方藥清單中的使用頻率不斷提高。此外，人工智慧驅動的數據分析正在重塑定價策略，透過利用真實世界的患者數據和競爭對手的洞察，根據疾病嚴重程度和治療持續時間創建靈活的分級定價模型。這將最終改善患者的用藥可近性，並維持市場成長。

全球Nivolumab單抗注射液市場按適應症、治療方法、終端用戶、分銷管道、市場發展水平和地區進行細分。依適應症分類，納武利尤單抗注射液市場分為黑色素瘤、肺癌、腎細胞癌和其他癌症。依治療方法分類，納武利尤單抗注射液市場分為單藥治療及聯合治療。依終端用戶分類，納武利尤單抗注射液市場分為醫院及腫瘤專科診所。依分銷管道分類，納武利尤單抗注射液市場分為醫院藥局和專科藥局。依劑量分類，納武利尤單抗注射液市場分為40毫克/4毫升、100毫克/10毫升和其他劑量。依地區分類，納武利尤單抗注射液市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球Nivolumab單抗注射劑市場成長要素

Nivolumab單抗核准的治療用途不斷擴展，涵蓋多種腫瘤適應症，這是推動全球市場成長的關鍵因素。隨著醫療專業人員擴大將該療法應用於更廣泛的患者群體，製藥公司正在加強促銷力度，進一步提升其市場佔有率。這種用途的多元化降低了對單一疾病領域的依賴，增強了醫生的信心，並促進了其在聯合治療中的應用。這些趨勢帶來了穩定的需求，並凸顯了該藥物在治療方案演變中的重要性。此外，越來越多的臨床證據表明，該藥物能夠改善患者的長期生存率，這促使保險公司更加認可該藥物，擴大了其覆蓋範圍，並使其更多地被納入標準治療方案中。

全球Nivolumab單抗注射劑市場的限制因素

Nivolumab的高昂價格給醫療預算帶來了巨大的經濟壓力，使得病人難以獲得治療，尤其是在醫療資源匱乏的地區。保險公司通常會提出嚴格的報銷要求，並要求提供全面的臨床療效證據，這可能會延遲治療的啟動，並阻礙市場成長。這種經濟負擔限制了該藥物的廣泛應用，尤其是在醫療資源有限、優先考慮成本效益的治療方案的發展中地區。此外，患者需要定期到門診進行靜脈注射，這會增加患者和醫療服務提供者的間接成本，進一步影響治療方案的選擇和市場動態。

全球Nivolumab單抗注射劑市場趨勢

受聯合治療免疫療法發展趨勢的推動，全球Nivolumab單抗注射劑市場正經歷顯著成長。醫療專業人員擴大將Nivolumab與各種查核點抑制劑、分子標靶療法和化療藥物聯合使用，以延長療效持續時間並應對抗藥性挑戰。新的臨床研究證實了這些聯合治療的療效顯著提升，進一步支持了這一趨勢，促使化療公司更加重視合作研發策略。因此，市場參與者正在拓展產品線並建立策略聯盟，從而改變處方習慣，擴大Nivolumab的潛在患者群體，進而重塑癌症治療格局。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

Nivolumab單抗注射液全球市場規模：依適應症分類

• 黑色素瘤
• 肺癌
• 腎臟細胞癌
• 其他

Nivolumab單抗注射液全球市場規模：依治療方法分類

• 單藥治療
• 聯合治療

Nivolumab單抗注射液全球市場規模：依最終用戶分類

• 醫院
• 癌症治療診所

Nivolumab單抗注射液全球市場規模：按分銷管道分類

• 醫院藥房
• 專科藥房

Nivolumab單抗注射液全球市場規模：以劑量強度分類

• 40 mg/4 mL
• 100 mg/10 mL
• 其他

全球Nivolumab單抗注射劑市場規模：依市場發展程度分類

• 已開發國家市場
• 新興市場

全球Nivolumab單抗注射劑市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Bristol Myers Squibb Company
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Limited
• Zydus Lifesciences Limited
• Biocon Limited
• Aurobindo Pharma Limited
• Cipla Limited
• Sandoz Group AG
• Amgen Inc.
• Samsung Bioepis Co., Ltd.
• Celltrion Inc.
• Shanghai Henlius Biotech, Inc.
• BeiGene, Ltd.
• Innovent Biologics, Inc.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• Junshi Biosciences
• Bio-Thera Solutions Ltd.
• Teva Pharmaceutical Industries Ltd.
• Fresenius Kabi AG
• Accord Healthcare Limited

結論與建議

Global Nivolumab Injection Market size was valued at USD 874.5 Million in 2024 and is poised to grow from USD 925.22 Million in 2025 to USD 1452.55 Million by 2033, growing at a CAGR of 5.8% during the forecast period (2026-2033).

The global nivolumab injection market represents a significant sector focused on a monoclonal antibody that inhibits PD-1, enabling the immune system to target malignant cells effectively. This drug serves as a vital treatment for conditions such as melanoma, non-small cell lung cancer, and renal cell carcinoma, generating substantial revenue for manufacturers like Bristol-Myers Squibb. The expanding reimbursement landscape is a key growth driver, as insurers increasingly acknowledge its impact on overall survival, particularly in metastatic melanoma, resulting in more frequent inclusion in formularies. Additionally, AI-driven data analytics is reshaping pricing strategies within this market by utilizing real-world patient data and competitor insights to create flexible, tiered pricing models that align with disease severity and treatment duration, ultimately enhancing patient access and sustaining market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Nivolumab Injection market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Nivolumab Injection Market Segments Analysis

The global nivolumab injection market is segmented by indication, therapy type, end user, distribution channel, dosage strength and region. Based on indication, the market is segmented into Melanoma, Lung Cancer, Renal Cell Carcinoma and Others. Based on therapy type, the market is segmented into Monotherapy and Combination Therapy. Based on end user, the market is segmented into Hospitals and Oncology Clinics. Based on distribution channel, the market is segmented into Hospital Pharmacies and Specialty Pharmacies. Based on dosage strength, the market is segmented into 40 mg/4 mL, 100 mg/10 mL and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Nivolumab Injection Market

The expansion of approved therapeutic uses for nivolumab across various oncology indications is a key factor driving growth in the global market. As healthcare providers increasingly adopt this treatment for a broader range of patients, pharmaceutical companies intensify their promotional efforts, which further enhances market presence. This diversification diminishes dependence on a single disease area, boosting physician confidence and fostering its integration into combination therapies. Such dynamics create consistent demand and affirm the drug's significance within advancing treatment protocols. Additionally, growing clinical evidence demonstrating long-term survival advantages bolsters payer acceptance, leading to broader reimbursement and encouraging its inclusion in standard treatment regimens.

Restraints in the Global Nivolumab Injection Market

The high price point of nivolumab presents a significant financial challenge for healthcare budgets, making it less accessible for patients, especially in resource-limited settings. Insurance providers frequently impose strict reimbursement requirements, necessitating comprehensive evidence of clinical efficacy, which can lead to delays in starting treatment and hinder market growth. This economic strain limits the widespread uptake of the medication, particularly in developing regions where healthcare resources favor more cost-effective options. Furthermore, the requirement for routine infusion appointments contributes to additional indirect costs for both patients and healthcare providers, further impacting treatment choices and overall market dynamics.

Market Trends of the Global Nivolumab Injection Market

The Global Nivolumab Injection market is witnessing a notable surge, driven by the rising trend of immunotherapy combinations. Healthcare professionals are increasingly incorporating nivolumab with various checkpoint inhibitors, targeted therapies, and chemotherapy treatments to improve response longevity and address resistance challenges. This trend is backed by emerging clinical research highlighting the enhanced efficacy of these combination therapies, prompting pharmaceutical companies to focus on co-development strategies. Consequently, market players are diversifying their product offerings and forming strategic partnerships, leading to evolving prescribing practices and expanding the potential patient base for nivolumab, thereby reshaping the landscape of oncology treatments.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Nivolumab Injection Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Melanoma
• Lung Cancer
• Renal Cell Carcinoma
• Others

Global Nivolumab Injection Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Monotherapy
• Combination Therapy

Global Nivolumab Injection Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Oncology Clinics

Global Nivolumab Injection Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies

Global Nivolumab Injection Market Size by Dosage Strength & CAGR (2026-2033)

• Market Overview
• 40 mg/4 mL
• 100 mg/10 mL
• Others

Global Nivolumab Injection Market Size by Geography & CAGR (2026-2033)

• Market Overview
• Developed Markets
• Emerging Markets

Global Nivolumab Injection Market Size & CAGR (2026-2033)

• North America (Indication, Therapy Type, End User, Distribution Channel, Dosage Strength, Geography)
  • US
  • Canada
• Europe (Indication, Therapy Type, End User, Distribution Channel, Dosage Strength, Geography)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Indication, Therapy Type, End User, Distribution Channel, Dosage Strength, Geography)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Indication, Therapy Type, End User, Distribution Channel, Dosage Strength, Geography)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Indication, Therapy Type, End User, Distribution Channel, Dosage Strength, Geography)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz Group AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Henlius Biotech, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Innovent Biologics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Junshi Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Thera Solutions Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Accord Healthcare Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations